Medtronic’s SPR Therapeutics deal signals a sharper move into earlier chronic pain intervention
Chronic pain care needs non-opioid options. Medtronic’s SPR Therapeutics deal tests whether temporary PNS can scale beyond niche adoption.
Why Donor Alliance and LifeSource are building a new model for transplant system performance
Organ donation needs trust and accountability. Vital Impact Health Group tests whether nonprofit OPO collaboration can raise transplant standards.
Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise
ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.
Is Avvio Medical building the next outpatient frontier in kidney stone and ureteral stone therapy?
Ureteral stones need faster care. Avvio Medical’s outpatient device tests whether microbubble lithotripsy can ease OR bottlenecks.
Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval
Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.
Could Hyundai Bioscience’s XAFTY become a crisis-response antiviral for Ebola and hantavirus?
Ebola urgency is rising, but broad-spectrum antivirals still face a proof gap. Hyundai Bioscience’s XAFTY now enters that debate.
How Araceli Biosciences is pushing live-cell imaging into ultra-high-throughput drug screening
AI drug discovery needs dynamic biology, not static snapshots. Araceli Biosciences is betting Endeavor Live Cell can close that data gap.
Regeneron’s $2.2bn Parabilis pact signals rising interest in next-generation conjugates
ADCs changed cancer delivery. Regeneron and Parabilis now want Helicon peptides to push conjugates inside harder-to-drug biology.
Samsung Bioepis targets Japan’s autoimmune market with ustekinumab biosimilar debut
Japan needs lower biologic costs. Samsung Bioepis’s NIPRO launch tests whether ustekinumab biosimilars can shift autoimmune care.
Bayer’s asundexian FDA priority review puts Factor XIa inhibition closer to a real stroke prevention test
Bayer needs a new cardiovascular growth engine. Asundexian’s FDA priority review now tests whether Factor XIa can move from promise to practice.